#Suven – Journey of my first 50 bagger…

I bought #Suven first in Apr 2013 around Rs 20…today after almost 7.5 years, its Rs 1000 (Suven pharma 920 adjusted for bonus + Suven Life 80)..CAGR of almost 68% for 7.5 years. I am fortunate to hold it throughout the journey and

add on multiple occasions on way up. Like to share my experience in this thread for everyone’s benefit..

First time I bought because I like the management focus on R&D. It had chosen the most difficult therapeutic area in pharma which is CNS and it was investing the cash

flow it used to earn from CRAMS. It also used to write off all the R&D expenses in the P&L instead of capitalizing it in BS. That gave me lot of comfort about management quality.

I kept on adding as funds keep coming. I remember giving a public presentation on Suven in

Mumbai at one analyst meet in Nov 2017 when it was trading at Rs 160. There was a huge call option embedded at that time in the form of SUVN-502. That would have been the blockbuster molecule if succeeded with market potential of $10 Bn plus..result was due in Dec 2019,

I loaded around 250-300 knowing the value of CRAMS business itself is more than 300.

SUVN-502 failed in phase-II trials, stock was down 15% from 300 to 250 in a single day, I added heavily. it was largest allocation in my portfolio because I knew the value of CRAMS business

Staying invested for long time compounds wealth as well as your business understanding. Higher allocation comes with higher conviction and higher conviction comes with higher degree of research…

#Suven got demerged. #Suvenlife was trading around Rs 20-30. I added further because it was having cash equal to Rs 25 per share. Later #Suvenpharma listed around 300, went down to 160 due to Corona meltdown…it was time to add more since one of the finest CRAMS business

with highest margins and highest return ratios was available at 7x P/E…

Don’t get anchored to your initial buying price. if the hypothesis is intact, ride it with conviction..add more

Today, combined value is Rs 1000 (Life + Pharma adj for bonus)…still 4x in a year

Suvenpharma is at its inflexion point..FY22 and further growth trajectory would be very different..Its doing capex of 920 crs which is more that its FY20 sales of which 320 crs getting commissioned by Mar 21…

How many companies does capex equal to their annual sales !!

and that too when the RoCE and operating margins are 40% plus…

Multibaggers can be achieved with Vision, patience and hard work…


• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with jeevan patwa

jeevan patwa Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @jeevanpatwa

15 Dec
#SuvenLife – Niche R&D play..very high risk and very high reward…key is right allocation…

Jazz Pharma was quoting around $0.5 in 2009, today its $150 and Mcap of $8.5 Bn on Nasdaq..almost 300x in 11 years. 80% of its total sales ($2.1 Bn) come from single drug Xyrem.
Axovant Lifescience, bought Alzheimer molecule from GSK, repackaged it and done phase-3 trials. Before starting the trials, the valuation was $2 Bn, just before announcing the data, it rose to $3 Bn. One of the leading broker put the target of $12 Bn if the trials succeeded..
but it failed in phase-3 trials. Current Mcap is $120 Mn…

This is R&D for New Chemical Entity (NCE)…very high risk and very high reward…

Brain-related illnesses, also known as CNS diseases, afflict more than 2 billion people worldwide. Diseases of the brain and mind range
Read 12 tweets
1 Nov
Suven Pharma – Becoming more relevant for customers…

“Crucial alliances were forged. Important investments were made. Strong associations sustained. We chose to widen our canvas. Heighten our vision”
“There is no API as of today. But we can manufacture APIs if our customers desire so”

“There is only one formulation as of today. Creating a basket of formulations for our CDMO customers could be an opportunity”
--- This is where Suven Pharma is moving to become more relevant for its customers…

It is only the penultimate intermediate until now. But straddling the phama value is the new customer mandate. Suven will be taking more wallet share of the customer by supplying the
Read 10 tweets
30 Oct
Laurus Labs – A process Innovator and a CRAMS player – deserves much higher multiple

With more than 100 process patents on his name, Dr Chhava has created a sustainable competitive advantage for Laurus Labs. Similar to drug innovator enjoying 15 years patent protection,
Laurus enjoys patent protection for its economically viable and innovative processes for different APIs like Efavirenz, Tenofovir, Dolutegravir, Metformin, Ivacaftor and many more..

Laurus developed novel and cost effective process for Efavirenz which reduced the cost by 50%...
Similar thing repeated when newer HIV regimen, Dolutegravir came into effect..Laurus developed its own proprietary novel and cost effective process for it..it is one of the few players having approval for TLE400...It has got process patent for Metformin where it can be
Read 9 tweets
29 Oct
Cloud & Digital – Multiple times bigger than Y2K for India…

Covid has accelerated cloud adoption in the world with more and more organization moving to cloud..Healthcare is shifting its data centers to cloud..patient records are getting moved to cloud..EHR software,
Strong results and management commentary from Accenture. Cloud services grew double digits..expect good nos from #IndianIT supported by cloud and digital services..
IT rally started... Mid cap IT will create new ATH
Read 5 tweets
30 Jul
Laurus Labs Q1FY21 results – My take – Operating leverage kicked in finally..Re-rating will follow..

When I bought Laurus Labs 2.5 years back, my hypothesis was…with the capacity that they put in ..it can generate 4000 crs top line and 15% NPM..
and I kept on asking management about the idle gross block in almost every conf. call…but the approvals got delayed and idle gross block was stationary..finally there was light at the end of tunnel…the hypothesis started playing out since Q4FY20…
formulation business started sweating…Depreciation, Interest, other fixed costs remained constant….Operating leverage kicked in finally….net profit swelled..
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!